The answer is simple ..NP .. Hopefully and all the other

New Post Public Reply Private Reply Replies (2) Message Board
reallypeople? HCIT #86742
590
The answer is simple ..NP .. Hopefully and all the other could be"s that come out of his mouth for YEARS ..No one trusts anything till revenue hits on the balance sheet. Yes really

""Posted On: 04/15/2021 1:28:34 PM

Posted By: HCIT
I know that the 200,000 vials are going to the PI's and it's not an EUA there, but just a distribution supply agreement yet, shares are still getting pummeled by traders. We hit a high of 3.29 today and here we are back fighting for the $3.00 mark yet again, currently at 3.05. And this happens all the time when we print news of more success. It's like the old commercial of a product that say's " and so on, and so on and so on and we get pummeled time after time as if no news was released of the good that CYDY is doing.

WHO is doing this and why? That is the $64,000 question. I have always and still say it's some one or some group of brokers/traders that do not want Cytodyn to have any kind of success in the pharmaceutical industry. Nefarious? Oh yeah it is. Some one or some group of people surely have deep pockets to persuade traders to stop any forward movement of our shares as to keep us behind the curtain so no investors or new investors can see the progress of what Leronlimab/Vyrologix has been able to attain so far.

What CYDY needs is an investor or a group of investors just like those that are pounding us into the deep zone, day after day to combat these entities the other way, up, just deep pockets of money to stop this incessant supply of sellers. I don't know what else to say as it just does not make sense with the progress CYDY has had as each day passes that we continually have forces to stop this company dead it it's tracks.

We need buyers to change the direction of our shares. I firmly believe that our share price with all the good news we continue to get, shares should be up and around 6.00/share, at least if not more. To get this, we need to broadcast our progress and defy the agencies and blast our success loud and clear otherwise we will sit here until substantial news and I mean BIG news like an EUA, somewhere on this planet to stop this onslaught of these traders and brokers or whom ever is doing this, ugh!

GLTA

HCIT


Read More: https://investorshangout.com/post/view?id=610...z6s7uXwWAJ





CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 34

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 36

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 38

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 62

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 47

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 45

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Mixed Markets: Analyzing Germany's Stock Performance

Updated Category News Views 211

Markets in Germany Prepare for Fluctuations As trading wrapped up on Wednesday, the German stock market exhibited a mixed bag of results. While certain sectors, such as Food & Beverages, Media, and Financial Services, reported gains, others faced setbacks. The Consumer & Cyclical, Construction, and Pharmaceuticals & Healthcare sectors saw declines, reflecting the market's...

Continue Reading
Teradyne's Q3 Earnings: Strong Performance and Future Growth Potential

Updated Category News Views 176

Teradyne's Q3 Earnings Exceed Expectations Teradyne Incorporated (NASDAQ: TER), a prominent player in automated test equipment, has released its third-quarter results, building a narrative of success and optimism. The company reported impressive sales figures of $737 million, with non-GAAP earnings per share (EPS) reaching $0.90, bolstered by a solid gross margin of...

Continue Reading
So-Young Plans to Revise ADS Ratio for Improved Trading

Updated Category News Views 163

So-Young's Strategic Shift in ADS Ratio So-Young International Inc. (NASDAQ: SY), a leading aesthetic treatment platform, has recently announced plans to change the ratio of its American depositary shares (ADSs) to Class A ordinary shares. This strategic decision aims to refine its trading dynamics, enhancing value for its shareholders. Details of the ADS Ratio Change The...

Continue Reading
Understanding Recent Developments at GitLab: Investor Insights

Updated Category News Views 78

Contextual Overview of GitLab's Recent Investor Challenges In a rapidly evolving technological landscape, GitLab Inc. stands at a critical juncture as investors navigate its latest developments and challenges. Recent announcements regarding financial performance have sparked interest and concern among stakeholders. Understanding the implications of these changes is...

Continue Reading
Celebrating 15 Years of Transformative Care at Senderra Pharmacy

Updated Category News Views 273

15 Years of Innovation in Specialty Pharmacy Senderra Specialty Pharmacy has proudly reached a remarkable milestone—15 years of providing top-tier healthcare solutions in the specialty pharmacy sector. This anniversary embodies a journey marked by significant advancements and unwavering commitment to revolutionizing patient care. Transforming Patient Experiences Since...

Continue Reading